Alejandro Lomniczi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alejandro Lomniczi has a total of 382 co-authors. Here are the top co-authors by number of shared publications:
- Sergio Raul Ojeda
Division of Neuroscience, Oregon National Primate Research Center/Oregon Health & Science University, Beaverton, OR 97006, USA
26 shared publications Sergio R. Ojeda
14 shared publicationsHollis Wright
Division of Neuroscience, Oregon National Primate Research Center/OHSU, Beaverton, USA
12 shared publications- Carlos Alejandro Toro
Spinal Cord Damage Research Center, Bronx, NY, United States
7 shared publications - Claudio Alberto Mastronardi
INPAC Research Group, Fundación Universitaria Sanitas, Bogotá, Colombia
7 shared publications - Juan Manuel Castellano
Department of Cell Biology, Physiology and Immunology, University of Córdoba, 14004 Córdoba, Spain
7 shared publications
Latest Publications
- 12 February 2026
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 114 (4) , 1127-1129
Effect of the Environmental Protection Agency reference dose of glyphosate on the ovarian function and cycle during the postnatal period
- 12 February 2026
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 114 (4) , 1127-1129
Effect of the Environmental Protection Agency reference dose of glyphosate on the ovarian function and cycle during the postnatal period
- 23 January 2026
- Published by Oxford University Press (OUP) in Reproduction
- Vol. 171 (2)
Evaluating the contraceptive potential of active immunization against gonadotropin-releasing hormone
Humans and rhesus macaques are known to express two molecular forms of gonadotropin-releasing hormone (GnRH-I and GnRH-II), which appear to differentially contribute to the regulation of the menstrual cycle. Specifically, there is evidence to suggest that GnRH-I is the primary mediator of negative estrogen feedback to the hypothalamus and pituitary gland, while GnRH-II is the primary mediator of the positive feedback that stimulates the preovulatory surge of luteinizing hormone. Therefore, it is plausible that selective silencing of GnRH-II would block ovulation and lay the platform for development of a novel contraceptive. To test this possibility female rhesus macaques were actively immunized against GnRH-II (and/or GnRH-I), and serum estradiol and progesterone concentrations were monitored for an additional ∼2.5 years. Despite multiple booster immunizations every ∼6 weeks, and elevated GnRH antibody titers, none of the animals ceased ovulating (i.e., revealed by monthly peaks of serum progesterone concentrations followed by menstruation). Taken together, these findings question the efficacy of GnRH vaccines as a stratagem for selectively blocking ovulation in humans. However, they do not negate the potential value of pharmacological interventions aimed at selectively silencing GnRH-II function and its involvement in stimulating the preovulatory luteinizing hormone surge.
- 23 January 2026
- Published by Oxford University Press (OUP) in Reproduction
- Vol. 171 (2)
Evaluating the contraceptive potential of active immunization against gonadotropin-releasing hormone
Humans and rhesus macaques are known to express two molecular forms of gonadotropin-releasing hormone (GnRH-I and GnRH-II), which appear to differentially contribute to the regulation of the menstrual cycle. Specifically, there is evidence to suggest that GnRH-I is the primary mediator of negative estrogen feedback to the hypothalamus and pituitary gland, while GnRH-II is the primary mediator of the positive feedback that stimulates the preovulatory surge of luteinizing hormone. Therefore, it is plausible that selective silencing of GnRH-II would block ovulation and lay the platform for development of a novel contraceptive. To test this possibility female rhesus macaques were actively immunized against GnRH-II (and/or GnRH-I), and serum estradiol and progesterone concentrations were monitored for an additional ∼2.5 years. Despite multiple booster immunizations every ∼6 weeks, and elevated GnRH antibody titers, none of the animals ceased ovulating (i.e., revealed by monthly peaks of serum progesterone concentrations followed by menstruation). Taken together, these findings question the efficacy of GnRH vaccines as a stratagem for selectively blocking ovulation in humans. However, they do not negate the potential value of pharmacological interventions aimed at selectively silencing GnRH-II function and its involvement in stimulating the preovulatory luteinizing hormone surge.
- Open Access
- 9 February 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (4) , e13498
Pituitary gonadotropin‐releasing hormone II as a possible mediator of positive estrogen feedback
It has previously been shown that rhesus macaques express two forms of gonadotropin‐releasing hormone (GNRH1 and GNRH2) in the hypothalamus and that both forms can stimulate the release of luteinizing hormone (LH) in vivo. However, while much has been published about the role of GNRH1 in reproduction, very little is known about the hypophysiotropic function of GNRH2. To shed light on this issue, we studied the expression pattern of these two genes in different parts of the monkey hypothalamus and pituitary gland under controlled conditions of circulating estrogen levels, using qPCR, liquid chromatography with tandem mass spectrometry and RNAscope. GNRH1/GNRH1 expression was found throughout the hypothalamus and was largely unaffected by circulating estradiol levels. In contrast, GNRH2/GNRH2 expression was found to be enhanced by long‐term treatment with estradiol and during the late follicular phase of the menstrual cycle, especially in the arcuate nucleus and pituitary gland. Together these findings suggest that pituitary GNRH2/GNRH2 (but not GNRH1/GNRH1) is induced by positive feedback‐like levels of estradiol. This novel finding raises the possibility that GNRH2 plays a major role in triggering the preovulatory LH surge in primates, not only at the level of the hypothalamus but also the pituitary gland.
- 9 February 2025
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (4) , e13498
Open AccessPituitary gonadotropin‐releasing hormone II as a possible mediator of positive estrogen feedback
It has previously been shown that rhesus macaques express two forms of gonadotropin‐releasing hormone (GNRH1 and GNRH2) in the hypothalamus and that both forms can stimulate the release of luteinizing hormone (LH) in vivo. However, while much has been published about the role of GNRH1 in reproduction, very little is known about the hypophysiotropic function of GNRH2. To shed light on this issue, we studied the expression pattern of these two genes in different parts of the monkey hypothalamus and pituitary gland under controlled conditions of circulating estrogen levels, using qPCR, liquid chromatography with tandem mass spectrometry and RNAscope. GNRH1/GNRH1 expression was found throughout the hypothalamus and was largely unaffected by circulating estradiol levels. In contrast, GNRH2/GNRH2 expression was found to be enhanced by long‐term treatment with estradiol and during the late follicular phase of the menstrual cycle, especially in the arcuate nucleus and pituitary gland. Together these findings suggest that pituitary GNRH2/GNRH2 (but not GNRH1/GNRH1) is induced by positive feedback‐like levels of estradiol. This novel finding raises the possibility that GNRH2 plays a major role in triggering the preovulatory LH surge in primates, not only at the level of the hypothalamus but also the pituitary gland.
- Open Access
- 26 July 2024
- Published by The Endocrine Society in Endocrinology
- Vol. 165 (9)
Changes in the Bile Acid Pool and Timing of Female Puberty: Potential Novel Role of Hypothalamic TGR5
Context The regulation of pubertal timing and reproductive axis maturation is influenced by a myriad of physiologic and environmental inputs yet remains incompletely understood. Objectives To contrast differences in bile acid isoform profiles across defined stages of reproductive maturity in humans and a rat model of puberty; to characterize the role of bile acid signaling via hypothalamic expression of bile acid receptor populations in the rodent model. Design Secondary analysis and pilot studies of clinical cohorts, rodent models, ex vivo analyses of rodent hypothalamic tissues. Main Outcome Measure Bile acid concentrations. Results Lower circulatory conjugated:deconjugated bile acid concentrations and higher total secondary bile acids were observed in the post-menarcheal versus pre/early-pubertal adolescents, with similar shifts observed in infantile (PN 14) versus early juvenile (PN 21) rats alongside increased tgr5 receptor mRNA expression within the mediobasal hypothalamus of female rats. 16S rRNA gene sequencing of the rodent gut microbiome across postnatal life revealed changes in the gut microbial composition predicted to have Bile Salt Hydrolase activity, which was observed in parallel with the increased deconjugated and increased concentrations of secondary bile acids. We show that TGR5-stimulated GnRH release from hypothalamic explants is mediated trough Kisspeptin-receptors and that early overexpression of human-TGR5 within the arcuate nucleus accelerates pubertal onset in female rats. Conclusion Bile acid isoform shifts along stages of reproductive maturation are conserved across rodents and humans, with pre-clinical models providing mechanistic insight for the neuroendocrine-hepatic-gut microbiome axis as a potential moderator of pubertal timing in females.
- 26 July 2024
- Published by The Endocrine Society in Endocrinology
- Vol. 165 (9)
Open AccessChanges in the Bile Acid Pool and Timing of Female Puberty: Potential Novel Role of Hypothalamic TGR5
Context The regulation of pubertal timing and reproductive axis maturation is influenced by a myriad of physiologic and environmental inputs yet remains incompletely understood. Objectives To contrast differences in bile acid isoform profiles across defined stages of reproductive maturity in humans and a rat model of puberty; to characterize the role of bile acid signaling via hypothalamic expression of bile acid receptor populations in the rodent model. Design Secondary analysis and pilot studies of clinical cohorts, rodent models, ex vivo analyses of rodent hypothalamic tissues. Main Outcome Measure Bile acid concentrations. Results Lower circulatory conjugated:deconjugated bile acid concentrations and higher total secondary bile acids were observed in the post-menarcheal versus pre/early-pubertal adolescents, with similar shifts observed in infantile (PN 14) versus early juvenile (PN 21) rats alongside increased tgr5 receptor mRNA expression within the mediobasal hypothalamus of female rats. 16S rRNA gene sequencing of the rodent gut microbiome across postnatal life revealed changes in the gut microbial composition predicted to have Bile Salt Hydrolase activity, which was observed in parallel with the increased deconjugated and increased concentrations of secondary bile acids. We show that TGR5-stimulated GnRH release from hypothalamic explants is mediated trough Kisspeptin-receptors and that early overexpression of human-TGR5 within the arcuate nucleus accelerates pubertal onset in female rats. Conclusion Bile acid isoform shifts along stages of reproductive maturation are conserved across rodents and humans, with pre-clinical models providing mechanistic insight for the neuroendocrine-hepatic-gut microbiome axis as a potential moderator of pubertal timing in females.
- Open Access
- 13 December 2023
- Published by Springer Nature in Clinical Epigenetics
- Vol. 15 (1) , 1-16
Methylation analysis by targeted bisulfite sequencing in large for gestational age (LGA) newborns: the LARGAN cohort
Background: In 1990, David Barker proposed that prenatal nutrition is directly linked to adult cardiovascular disease. Since then, the relationship between adult cardiovascular risk, metabolic syndrome and birth weight has been widely documented. Here, we used the TruSeq Methyl Capture EPIC platform to compare the methylation patterns in cord blood from large for gestational age (LGA) vs adequate for gestational age (AGA) newborns from the LARGAN cohort. Results: We found 1672 differentially methylated CpGs (DMCs) with a nominal p < 0.05 and 48 differentially methylated regions (DMRs) with a corrected p < 0.05 between the LGA and AGA groups. A systems biology approach identified several biological processes significantly enriched with genes in association with DMCs with FDR < 0.05, including regulation of transcription, regulation of epinephrine secretion, norepinephrine biosynthesis, receptor transactivation, forebrain regionalization and several terms related to kidney and cardiovascular development. Gene ontology analysis of the genes in association with the 48 DMRs identified several significantly enriched biological processes related to kidney development, including mesonephric duct development and nephron tubule development. Furthermore, our dataset identified several DNA methylation markers enriched in gene networks involved in biological pathways and rare diseases of the cardiovascular system, kidneys, and metabolism. Conclusions: Our study identified several DMCs/DMRs in association with fetal overgrowth. The use of cord blood as a material for the identification of DNA methylation biomarkers gives us the possibility to perform follow-up studies on the same patients as they grow. These studies will not only help us understand how the methylome responds to continuum postnatal growth but also link early alterations of the DNA methylome with later clinical markers of growth and metabolic fitness.
- 13 December 2023
- Published by Springer Nature in Clinical Epigenetics
- Vol. 15 (1) , 1-16
Open AccessMethylation analysis by targeted bisulfite sequencing in large for gestational age (LGA) newborns: the LARGAN cohort
Background: In 1990, David Barker proposed that prenatal nutrition is directly linked to adult cardiovascular disease. Since then, the relationship between adult cardiovascular risk, metabolic syndrome and birth weight has been widely documented. Here, we used the TruSeq Methyl Capture EPIC platform to compare the methylation patterns in cord blood from large for gestational age (LGA) vs adequate for gestational age (AGA) newborns from the LARGAN cohort. Results: We found 1672 differentially methylated CpGs (DMCs) with a nominal p < 0.05 and 48 differentially methylated regions (DMRs) with a corrected p < 0.05 between the LGA and AGA groups. A systems biology approach identified several biological processes significantly enriched with genes in association with DMCs with FDR < 0.05, including regulation of transcription, regulation of epinephrine secretion, norepinephrine biosynthesis, receptor transactivation, forebrain regionalization and several terms related to kidney and cardiovascular development. Gene ontology analysis of the genes in association with the 48 DMRs identified several significantly enriched biological processes related to kidney development, including mesonephric duct development and nephron tubule development. Furthermore, our dataset identified several DNA methylation markers enriched in gene networks involved in biological pathways and rare diseases of the cardiovascular system, kidneys, and metabolism. Conclusions: Our study identified several DMCs/DMRs in association with fetal overgrowth. The use of cord blood as a material for the identification of DNA methylation biomarkers gives us the possibility to perform follow-up studies on the same patients as they grow. These studies will not only help us understand how the methylome responds to continuum postnatal growth but also link early alterations of the DNA methylome with later clinical markers of growth and metabolic fitness.
- Open Access
- 12 January 2023
- Published by S. Karger AG in Neuroendocrinology
- Vol. 113 (5) , 577-578
Erratum
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- 12 January 2023
- Published by S. Karger AG in Neuroendocrinology
- Vol. 113 (5) , 577-578
Open AccessErratum
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Top Cited Papers
- 5 January 2023
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 11 (3) , 203-216
Molecular basis of normal and pathological puberty: from basic mechanisms to clinical implications
- 5 January 2023
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 11 (3) , 203-216
Top Cited PapersMolecular basis of normal and pathological puberty: from basic mechanisms to clinical implications
- 3 November 2021
- Published by Springer Nature in Nature
- Vol. 599 (7885) , 377-379
A mediator of metabolic signals influences puberty and growth
- 3 November 2021
- Published by Springer Nature in Nature
- Vol. 599 (7885) , 377-379
A mediator of metabolic signals influences puberty and growth
- Open Access
- 21 January 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-17
Polycomb represses a gene network controlling puberty via modulation of histone demethylase Kdm6b expression
Female puberty is subject to Polycomb Group (PcG)-dependent transcriptional repression. Kiss1, a puberty-activating gene, is a key target of this silencing mechanism. Using a gain-of-function approach and a systems biology strategy we now show that EED, an essential PcG component, acts in the arcuate nucleus of the hypothalamus to alter the functional organization of a gene network involved in the stimulatory control of puberty. A central node of this network is Kdm6b, which encodes an enzyme that erases the PcG-dependent histone modification H3K27me3. Kiss1 is a first neighbor in the network; genes encoding glutamatergic receptors and potassium channels are second neighbors. By repressing Kdm6b expression, EED increases H3K27me3 abundance at these gene promoters, reducing gene expression throughout a gene network controlling puberty activation. These results indicate that Kdm6b repression is a basic mechanism used by PcG to modulate the biological output of puberty-activating gene networks.
- 21 January 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-17
Open AccessPolycomb represses a gene network controlling puberty via modulation of histone demethylase Kdm6b expression
Female puberty is subject to Polycomb Group (PcG)-dependent transcriptional repression. Kiss1, a puberty-activating gene, is a key target of this silencing mechanism. Using a gain-of-function approach and a systems biology strategy we now show that EED, an essential PcG component, acts in the arcuate nucleus of the hypothalamus to alter the functional organization of a gene network involved in the stimulatory control of puberty. A central node of this network is Kdm6b, which encodes an enzyme that erases the PcG-dependent histone modification H3K27me3. Kiss1 is a first neighbor in the network; genes encoding glutamatergic receptors and potassium channels are second neighbors. By repressing Kdm6b expression, EED increases H3K27me3 abundance at these gene promoters, reducing gene expression throughout a gene network controlling puberty activation. These results indicate that Kdm6b repression is a basic mechanism used by PcG to modulate the biological output of puberty-activating gene networks.
- Top Cited Papers
- 7 December 2020
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 17 (2) , 83-96
Cellular and molecular features of EDC exposure: consequences for the GnRH network
The onset of puberty and the female ovulatory cycle are important developmental milestones of the reproductive system. These processes are controlled by a tightly organized network of neurotransmitters and neuropeptides, as well as genetic, epigenetic and hormonal factors, which ultimately drive the pulsatile secretion of gonadotropin-releasing hormone. They also strongly depend on organizational processes that take place during fetal and early postnatal life. Therefore, exposure to environmental pollutants such as endocrine-disrupting chemicals (EDCs) during critical periods of development can result in altered brain development, delayed or advanced puberty and long-term reproductive consequences, such as impaired fertility. The gonads and peripheral organs are targets of EDCs, and research from the past few years suggests that the organization of the neuroendocrine control of reproduction is also sensitive to environmental cues and disruption. Among other mechanisms, EDCs interfere with the action of steroidal and non-steroidal receptors, and alter enzymatic, metabolic and epigenetic pathways during development. In this Review, we discuss the cellular and molecular consequences of perinatal exposure (mostly in rodents) to representative EDCs with a focus on the neuroendocrine control of reproduction, pubertal timing and the female ovulatory cycle.
- 7 December 2020
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 17 (2) , 83-96
Top Cited PapersCellular and molecular features of EDC exposure: consequences for the GnRH network
The onset of puberty and the female ovulatory cycle are important developmental milestones of the reproductive system. These processes are controlled by a tightly organized network of neurotransmitters and neuropeptides, as well as genetic, epigenetic and hormonal factors, which ultimately drive the pulsatile secretion of gonadotropin-releasing hormone. They also strongly depend on organizational processes that take place during fetal and early postnatal life. Therefore, exposure to environmental pollutants such as endocrine-disrupting chemicals (EDCs) during critical periods of development can result in altered brain development, delayed or advanced puberty and long-term reproductive consequences, such as impaired fertility. The gonads and peripheral organs are targets of EDCs, and research from the past few years suggests that the organization of the neuroendocrine control of reproduction is also sensitive to environmental cues and disruption. Among other mechanisms, EDCs interfere with the action of steroidal and non-steroidal receptors, and alter enzymatic, metabolic and epigenetic pathways during development. In this Review, we discuss the cellular and molecular consequences of perinatal exposure (mostly in rodents) to representative EDCs with a focus on the neuroendocrine control of reproduction, pubertal timing and the female ovulatory cycle.